Women's Weight Loss: How GLP-1 Medications Work for Women
%20Medium.jpeg)
Women's bodies respond to weight management differently than men's, and the reasons are physiological, not motivational. Understanding these differences is the starting point for any conversation about effective treatment.
Hormonal influence on fat storage. Oestrogen and progesterone play a direct role in where and how the body stores fat. Before menopause, oestrogen promotes subcutaneous fat storage (particularly around the hips and thighs), which serves a protective biological function. As oestrogen levels decline during perimenopause and menopause, fat distribution shifts toward visceral storage around the abdomen. This is not simply a cosmetic change. Visceral fat is metabolically active and is associated with higher risks of cardiovascular disease, type 2 diabetes, and metabolic syndrome, according to research published in the journal Obesity Reviews.
Metabolic rate differences. Women generally have a lower basal metabolic rate than men, partly because of differences in lean muscle mass. This means women burn fewer calories at rest, and the gap tends to widen with age. The National Health and Medical Research Council (NHMRC) guidelines on obesity management acknowledge that caloric restriction alone is often insufficient for sustained weight management in women, particularly after 40.
Menstrual cycle and appetite regulation. The hormonal fluctuations of the menstrual cycle directly affect appetite, cravings, and energy expenditure. Research published in the American Journal of Clinical Nutrition shows that energy intake tends to increase during the luteal phase (the two weeks before a period), driven by changes in progesterone and serotonin. This is not emotional eating. It is a measurable, hormonally mediated shift in hunger signalling.
Pregnancy, postpartum, and lasting metabolic changes. Pregnancy fundamentally alters metabolic pathways. Gestational weight gain, changes in insulin sensitivity, and shifts in body composition can persist well beyond the postpartum period. For many women, the weight gained during pregnancy proves resistant to the strategies that worked before, and this is a physiological reality rather than a failure of effort.
The psychological dimension. Weight carries a particular emotional burden for many women. Years of dieting, conflicting advice, and cultural pressure create a complex relationship with food and body image. Effective weight management care must acknowledge this reality without judgment. The goal is health, not a number on a scale.
These factors help explain why a one-size-fits-all approach to weight management so often falls short for women. They also help explain why a class of medication that works on the hormonal signalling pathways governing hunger and satiety has generated so much interest.
GLP-1 stands for glucagon-like peptide-1. It is a hormone produced naturally in the gut after eating. Its role is to signal the brain that food has arrived, promote a feeling of fullness, and help regulate blood sugar by stimulating insulin release from the pancreas.
GLP-1 receptor agonists are prescription medications that mimic and enhance this natural hormonal signal. They were originally developed for managing type 2 diabetes and have since been recognised by the Therapeutic Goods Administration (TGA) for their significant role in weight management.
The medications produce three main effects that are relevant to weight management.
Appetite reduction. GLP-1 receptor agonists act on appetite-regulating centres in the brain, specifically the hypothalamus and brainstem. They dampen hunger signals and enhance the sensation of fullness. For many patients, this is the most noticeable change. Food remains enjoyable, but the persistent background noise of hunger becomes significantly quieter.
Slower gastric emptying. The medications slow the rate at which food leaves the stomach, meaning patients feel satisfied for longer after meals. This naturally leads to smaller portions and less frequent eating without the constant battle of willpower that characterises most caloric restriction diets.
Improved blood sugar regulation. By enhancing insulin release and suppressing glucagon (a hormone that raises blood sugar), GLP-1 medications help stabilise glucose levels throughout the day. This can reduce the energy crashes and sugar cravings that make sustained dietary changes so difficult for many women.
Large-scale clinical trials published in The New England Journal of Medicine and The Lancet have demonstrated that GLP-1 receptor agonists, when used alongside lifestyle modifications, may support meaningful and sustained weight reduction. It is important to note that these medications are most effective as part of a comprehensive approach that includes dietary changes, physical activity where appropriate, and ongoing medical supervision.
GLP-1 medications are prescription-only in Australia. They are not available over the counter, and they require a medical consultation and clinical assessment before they can be prescribed. This is by design. The medication needs to be matched to the individual, the dose needs to be carefully titrated, and side effects need to be monitored by a qualified clinician.
For many women, the relationship between weight and hormones becomes most acute during perimenopause and menopause. This is the life stage where weight management often feels like it stops responding to the strategies that once worked, and there are clear biological reasons why.
The oestrogen-weight connection. Oestrogen plays a central role in regulating metabolism, fat distribution, and insulin sensitivity. During perimenopause (which can begin in a woman's early 40s and last four to eight years according to the Australasian Menopause Society), oestrogen levels fluctuate unpredictably before eventually declining. This decline is associated with several metabolic changes that promote weight gain.
Insulin sensitivity decreases, meaning the body becomes less efficient at processing glucose. Fat storage shifts from subcutaneous deposits around the hips and thighs to visceral fat around the abdomen. Lean muscle mass decreases, reducing basal metabolic rate. And appetite regulation pathways are disrupted, making it harder to recognise and respond to genuine hunger and fullness signals.
Why traditional dieting often fails at menopause. Caloric restriction, which is the foundation of most conventional weight loss advice, can be counterproductive during the menopausal transition. Research published by the NHMRC and in the journal Menopause suggests that severe caloric restriction in menopausal women may further reduce metabolic rate, accelerate muscle loss, and worsen the hormonal disruption that is contributing to weight gain in the first place. It can become a frustrating cycle where eating less leads to a slower metabolism, which leads to weight plateaus, which leads to eating even less.
Where GLP-1 medications may help. For women experiencing menopause-related weight gain, GLP-1 receptor agonists offer a different mechanism of action. Rather than relying on willpower to override disrupted hunger signals, these medications work at the hormonal level to restore the appetite-regulating signals that declining oestrogen has weakened.
Clinical studies suggest that GLP-1 medications may be particularly relevant for postmenopausal women because they address the underlying hormonal disruption rather than simply reducing caloric intake. They may also support improvements in insulin sensitivity and blood sugar regulation, both of which are commonly affected during the menopausal transition.
It is worth emphasising that menopause-related weight management is best approached as part of a broader conversation with your doctor. For some women, hormone replacement therapy (HRT) may also play a role, and the interaction between HRT and weight management medication should be assessed by a GP who understands your full health picture.
There is no single answer to this question, and that is precisely why these medications require a prescription and a proper medical assessment. Several GLP-1 receptor agonist formulations have been approved by the TGA for use in Australia, and they differ in their dosing schedules, administration methods, side effect profiles, and PBS eligibility.
Your GP will consider several factors when determining which medication, if any, is appropriate for your situation.
BMI and eligibility criteria. Australian clinical guidelines generally recommend considering weight management medication for adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidaemia, or obstructive sleep apnoea. These thresholds are established by the NHMRC and the RACGP. PBS subsidies, where available, may have additional eligibility requirements.
Your health history. Pre-existing conditions such as a personal or family history of medullary thyroid carcinoma, pancreatitis, or severe gastrointestinal disease may affect whether GLP-1 medications are suitable. Your GP will review your full medical history before making a recommendation.
Other medications. GLP-1 receptor agonists can interact with certain other medications, including insulin and some oral diabetes treatments. If you are taking other medications, your doctor will assess potential interactions.
Your preferences and lifestyle. Some GLP-1 medications are administered as a weekly injection, while others may be taken daily. Your GP can discuss the options and help you choose a formulation that fits your routine and comfort level.
Tolerability. The most commonly reported side effects of GLP-1 medications include nausea, constipation, diarrhoea, and reduced appetite (beyond the therapeutic effect). These are typically most noticeable during the early weeks of treatment and tend to settle as the dose is titrated upward. Starting on a low dose and increasing gradually is standard practice recommended by the RACGP, specifically to minimise these effects.
The key point is that the right medication for you is the one your doctor prescribes after a thorough assessment of your individual health, goals, and circumstances. Be cautious of any service that offers to prescribe weight loss medication without a comprehensive consultation.
Every patient's experience with GLP-1 medication is different, and it is important to set realistic expectations. The following is a general guide to what many women experience, though individual results vary.
Weeks 1 to 4 (starting dose). Most patients notice a reduction in appetite within the first one to two weeks. Portion sizes tend to decrease naturally. Some nausea or mild gastrointestinal discomfort is common during this period. Energy levels may fluctuate as the body adjusts. Your GP will check in to monitor how you are tolerating the medication.
Weeks 4 to 8 (dose titration). If the starting dose is well tolerated, your GP will typically increase it at this point. Side effects often begin to settle. Many patients report feeling more in control of their eating patterns, with less preoccupation with food between meals. Some women notice early changes in how their clothes fit and how they feel day to day.
Weeks 8 to 16 (approaching therapeutic dose). As the dose reaches its target level, the effects tend to become more consistent. Clinical trials suggest that meaningful changes are typically observed within this timeframe when medication is combined with lifestyle modifications. Your GP will repeat blood work to track changes in metabolic markers including blood sugar, cholesterol, and liver function.
Months 4 to 12 and beyond. Ongoing treatment is monitored at regular intervals, typically every six to twelve weeks once the dose is stable. Weight management is a long-term process, and clinical evidence suggests that sustained results are best achieved when medication is continued alongside dietary and lifestyle changes, under medical supervision.
It is essential to understand that GLP-1 medications are not a quick fix. They work best as one component of a comprehensive weight management plan that includes nutritional guidance, physical activity where appropriate, and regular follow-up with a GP who knows your health story. The medication creates a more level playing field by addressing the hormonal signals that make weight management so difficult, but it works alongside your own efforts rather than replacing them.
Ready to explore your options?
Accessing weight management care in Australia has traditionally meant long wait times for GP appointments, limited availability of doctors with specific expertise in obesity medicine, and the practical challenges of fitting in-person visits around work, family, and life.
Online-first clinics have changed this. A weight management consultation can now take place from your home, your office, or wherever is most convenient, with the same clinical rigour as an in-person visit.
Here is what the process typically looks like.
Step 1: Book an appointment. Choose a time that works for you. A good online-first clinic will offer appointments seven days a week, including evenings and weekends, so that healthcare fits around your schedule rather than the other way around.
Step 2: Complete your health profile. Before your consultation, you will provide information about your health history, current medications, any previous weight management attempts, and your goals. This allows your doctor to arrive at the consultation informed and ready to have a meaningful conversation.
Step 3: Consult with a GP. Your consultation is with a registered Australian GP. It is a real medical appointment, not a questionnaire or a chatbot. Your doctor will assess your eligibility for weight management medication based on clinical guidelines, discuss the options, explain the benefits and risks, and answer your questions.
Step 4: Receive your treatment plan. If your GP determines that GLP-1 medication is clinically appropriate, they will issue a prescription and outline your treatment plan. This includes the titration schedule, dietary guidance, monitoring timeline, and follow-up appointments.
Step 5: Ongoing care. This is the part that matters most. Weight management is not a single appointment. It is a clinical relationship. Regular follow-ups allow your GP to monitor your progress, adjust your treatment, and address any concerns as they arise.
Abby Health is Australia's largest online-first clinic, and our care network includes GPs with experience in medically supervised weight management programs for women.
Here is what makes our approach different.
Continuity of care. 71% of Abby Health patients rebook with the same doctor. This means the GP managing your weight loss understands your full health story, tracks your progress over time, and adjusts your treatment based on how you are actually responding. You are not starting from scratch at every visit.
Accessibility. Consultations are available seven days a week, 365 days a year, including evenings and weekends. Appointments are bulk billed for eligible patients with a valid Medicare card, removing one of the most common barriers to accessing regular care.
Clinical decision support. Abby AI, our medical AI, prepares every consultation by surfacing your health history, previous notes, and relevant clinical information. This means your doctor spends less time reviewing records and more time focused on you. Abby AI supports clinicians. It never diagnoses, prescribes, or replaces clinical judgment.
A medically supervised program. Our weight management pathway includes initial assessment, medication management where appropriate, nutritional guidance, regular monitoring, and follow-up blood work. It is a structured clinical program, not a prescription service.
If you are considering weight loss medication and want to speak with a GP who will take the time to understand your situation, you can book an appointment with Abby Health today.
Editorial Standards
Notice something that doesn’t look right? Let us know at support@abbyhealth.app
Authors
.avif)
